Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Invested Capital (2016 - 2025)

Lineage Cell Therapeutics' Invested Capital history spans 16 years, with the latest figure at $43.3 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 43.72% year-over-year to $43.3 million; the TTM value through Dec 2025 reached $43.3 million, down 43.72%, while the annual FY2025 figure was $43.3 million, 43.72% down from the prior year.
  • Invested Capital reached $43.3 million in Q4 2025 per LCTX's latest filing, up from $20.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $123.6 million in Q2 2021 to a low of $20.8 million in Q3 2025.
  • Average Invested Capital over 5 years is $75.3 million, with a median of $71.7 million recorded in 2022.
  • Peak YoY movement for Invested Capital: skyrocketed 32.57% in 2021, then plummeted 67.9% in 2025.
  • A 5-year view of Invested Capital shows it stood at $90.9 million in 2021, then fell by 20.77% to $72.0 million in 2022, then fell by 13.92% to $62.0 million in 2023, then increased by 24.17% to $77.0 million in 2024, then crashed by 43.72% to $43.3 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Invested Capital are $43.3 million (Q4 2025), $20.8 million (Q3 2025), and $47.1 million (Q2 2025).